| dimethyl fumarate / Generic mfg. |
IIT6, NCT01945359: Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design |
|
|
| Completed | N/A | 30 | US | | Rocky Mountain MS Research Group, LLC, Biogen | Relapsing Remitting Multiple Sclerosis | 09/14 | 06/15 | | |
NCT02159573: Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) |
|
|
| Completed | N/A | 530 | US | natalizumab, BG00002, Tysabri, dimethyl fumarate, BG00012, Tecfidera, DMF | Biogen | Relapsing-Remitting Multiple Sclerosis | 01/15 | 01/15 | | |
NCT02419638: Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS |
|
|
| Withdrawn | N/A | 0 | US | Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate) | Brigham and Women's Hospital, EMD Serono | Multiple Sclerosis | 12/15 | 02/16 | | |
NCT01903291: Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS |
|
|
| Completed | N/A | 333 | US | dimethyl fumarate, Tecfidera, BG00012, DMF | Biogen | Relapsing Forms of Multiple Sclerosis | 02/16 | 02/16 | | |
|
| Completed | N/A | 483 | US | dimethyl fumarate, DMF; Tecfidera, BG00012 | Biogen | Multiple Sclerosis | 02/16 | 02/16 | | |
IMPROVE, NCT02323269: Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) |
|
|
| Terminated | N/A | 24 | Canada | dimethyl fumarate, DMF, BG00012, Tecfidera | Biogen | Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis | 03/16 | 03/16 | | |
EFFECT, NCT02776072: Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) |
|
|
| Completed | N/A | 2978 | US, Canada, Europe, RoW | | Biogen | Multiple Sclerosis | 12/16 | 12/16 | | |
NCT02969304: Study of Utilization Patterns of Dimethyl Fumarate in Germany |
|
|
| Completed | N/A | 930 | Europe | dimethyl fumarate, Tecfidera, DMF, BG00012 | Biogen | Multiple Sclerosis | 03/17 | 03/17 | | |
PROTRACT, NCT02823951: Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® |
|
|
| Completed | N/A | 479 | US, Canada | Rebif, Tecfidera | IMS HEALTH GmbH & Co. OHG, EMD Serono | Relapsing-remitting Multiple Sclerosis | 04/17 | 02/18 | | |
| Terminated | N/A | 4 | US | Dimethyl fumarate, Tecfidera | Oregon Health and Science University, Biogen | Multiple Sclerosis | 07/18 | 07/18 | | |
